Cite
Miller AL, Garcia PL, Fehling SC, et al. The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers (Basel). 2021;13(14)doi: 10.3390/cancers13143470.
Miller, A. L., Garcia, P. L., Fehling, S. C., Gamblin, T. L., Vance, R. B., Council, L. N., Chen, D., Yang, E. S., van Waardenburg, R. C. A. M., & Yoon, K. J. (2021). The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers, 13(14), . https://doi.org/10.3390/cancers13143470
Miller, Aubrey L, et al. "The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer." Cancers vol. 13,14 (2021). doi: https://doi.org/10.3390/cancers13143470
Miller AL, Garcia PL, Fehling SC, Gamblin TL, Vance RB, Council LN, Chen D, Yang ES, van Waardenburg RCAM, Yoon KJ. The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers (Basel). 2021 Jul 11;13(14). doi: 10.3390/cancers13143470. PMID: 34298684; PMCID: PMC8303731.
Copy
Download .nbib